Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions

Journal of Medical Virology

Volumn 81, Issue 4, 2009, Pages 703-712

  Bello, Barbara Dal ^a   Spinillo, Arsenio ^a   Alberizzi, Paola ^a   Cesari, Stefania ^a   Gardella, Barbara ^a   D'Ambrosio, Gioacchino ^a   Roccio, Marianna ^a   Silini, Enrico Maria ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Cancer; Cervix; CIN; Coinfection; HPV

Indexed keywords

ADULT; AGED; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; MAJOR CLINICAL STUDY; PRECANCER; PREVALENCE; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; WART VIRUS; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; ITALY; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; RISK FACTOR; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

VIRUS DNA;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; ITALY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 62849115985     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21429     Document Type: Article

References (36)

1. Bachtiary B, Obermair A, Dreier B, Birner P, Breitenecker G, Knocke TH, Selzer E, Potter R. 2002. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int J Cancer 102:237-243.
2. Bosch X, Harper D. 2006. Prevention strategies ofcervical cancer in the HPV vaccine era. Gynecol Oncol 103:21-24.
3. Capra G, Giovannelli L, Bellavia C, Migliore MC, Caleca MP, Perino A, Ammatuna P. 2008. HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Virus Res 133:195-200.
4. Castle PE, Solomon D, Schiffman M, Wheeler CM. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97:1066-1071.
5. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. 2008. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 46:109-117.
6. Centurioni MG, Puppo A, Merlo DF, Pasciucco G, Cusimano ER, Sirito R, Gustavino CA. 2005. Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis 5:77.
7. Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ, Hagensee ME. 2005. Prevalence and clustering patterns ofhuman papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 14:2439-2445.
8. Clifford GM, Goncalves MA, Franceschi S. 2006. Human papilloma- virus types among women infected with HIV: A meta-analysis. AIDS 20:2337-2344.
9. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E. 2004. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 57:68-72.
10. Cuzick J. 1985. A Wilcoxon-type test for trend. Stat Med 4:87-90.
11. Fife KH, Cramer HM, Scoeder JM, Brown DR. 2001. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol 64:550-559.
12. Gargiulo F, De Francesco MA, Sceiber C, Ciravolo G, Salinaro F, Valloncini B, Manca N. 2007. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 125:176-182.
13. Greenland S, Drescher K. 1993. Maximum likelihood estimation ofthe attributable fraction from logistic models. Biometrics 49:865-872.
14. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. 2005. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste. Costa Rica J Infect Dis 191:1796-1807.
15. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423-428.
16. IARC. 2005. Human papillomaviruses, Vol. 90. Lyon, France: International Agency for Research on Cancer.
17. Kleter B, van Doorn LJ, Scauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W. 1999. Development and clinical evaluation of a highly sensitive PCR- reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508-2517.
18. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651.
19. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M. 2001. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183:8-15.
20. Mendez F, Munoz N, Posso H, Molano M, Moreno V, van den Brule AJ, Ronderos M, Meijer C, Munoz A. 2005. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 192:1158-1165.
21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
22. Plummer M, Schiffman M, Castle PE, Maucort- Boulch D, Wheeler CM. 2007. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 195:1582-1589.
23. Roden R, Wu TC. 2006. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6:753-763.
24. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R. 2008. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513-517.
25. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. 2001. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184:1508-1517.
26. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL. 2003a. Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 12:1029-1037.
27. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. 2003b. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 30:581 -587.
28. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr., Young N. 2002. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. J Am Med Assoc 287:2114-2119.
29. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, Koutsky LA. 2000. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 182:1097-1102.
30. Tornesello ML, Duraturo ML, Botti G, Greggi S, Piccoli R, De Palo G, Montella M, Buonaguro L, Buonaguro FM. 2006. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithe- lial lesions and invasive cervical carcinoma in the Italian population. J Med Virol 78:1663-1672.
31. Trottier H, Franco EL. 2006. The epidemiology of genital human papillomavirus infection. Vaccine 24:S1-S15.
32. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2006. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 15:1274-1280.
33. Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL. 2008. Type-specific duration of human papillomavirus infection: Implications for human papillo- mavirus screening and vaccination. J Infect Dis 197:1436-1447.
34. van der GraafY, Molijn A, Doornewaard H, Quint W, van Doorn LJ, van den Tweel J. 2002. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 156:158-164.
35. van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol 44:3122-3129.
36. Wheeler CM, Hunt WC, Schiffman M, Castle PE. 2006. Human papillomavirus genotypes and the cumulative 2-year risk ofcervical precancer. J Infect Dis 194:1291-1299.